Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia (RRAIHA01)

This is an open, one-armed, prospective study through Peking Union Medical College Hospital that is looking to assess how well a single dose of anti-CD20 monoclonal antibody combined with bortezomib (a type of chemotherapy) works in the treatment of relapsed refractory autoimmune hemolytic anemia. The study is also open to patients who have secondary Evans syndrome. Participants must be adults between the ages of 18-80 years.



back to top

Charity NavigatorGuideStar Seal NORD Member BadgeTHSNA logo